[Special Stock] Dreamtech Identifies COVID-19, MERS, SARS Infection by Smell in 30 Seconds

[Asia Economy Reporter Hyungsoo Park] Dreamtech has been on the rise for two consecutive days following the news that it jointly developed a diagnostic device based on an 'electronic nose solution' capable of detecting COVID-19 infection in collaboration with Israeli startup Nanocent.

As of 9:24 AM on the 5th, Dreamtech is trading at 9,720 KRW, up 16.65% from the previous day.

The previous day, Dreamtech's stock price surged by 25%.

The diagnostic device developed by Dreamtech and Nanocent collects exhaled breath using a dedicated breath bag, and when attached to an analysis device, it can determine COVID-19 infection status within 30 seconds. The principle is to diagnose viral infection by identifying specific gases contained in the exhaled breath. The electronic nose solution is an electronic device that distinguishes odors and analyzes chemical components.

Although in the early stages of development, the company expects that by utilizing the electronic nose solution, it can be used as an initial screening system for many people in multi-use facilities such as airports, hospitals, and stores within a short time. It can also be applied to acute respiratory syndromes such as MERS and SARS, in addition to COVID-19.

Dreamtech holds a 6.7% stake in Nanocent. Dreamtech and Nanocent are preparing for mass production of the device with the goal of obtaining European Conformity (CE) certification next month.

This content was produced with the assistance of AI translation services.